Q2 2025 DaVita Inc Earnings Call Transcript
Key Points
- DaVita Inc (DVA) reported a solid quarter with financial commitments met, supported by strong clinical performance and disciplined execution.
- The company achieved adjusted operating income and adjusted earnings per share slightly ahead of expectations.
- DaVita Inc (DVA) is optimistic about the potential of breakthrough technologies and new drug classes to improve patient care and outcomes.
- The company has a proven track record of managing costs effectively, which helps offset current volume weaknesses.
- DaVita Inc (DVA) reaffirmed its guidance range for adjusted operating income and adjusted earnings per share for the year, despite the negative impact of a cyber incident.
- US treatments per day declined by 1.1% compared to the second quarter of 2024, with a higher-than-expected mistreatment rate attributed to a cyber incident.
- The cyber incident had a significant financial impact, with discrete costs of approximately $13 million and a negative effect on treatment volume and revenue per treatment.
- Revenue per treatment growth is expected to be near the lower end of the original range due to the cyber incident and lower dispensing volumes of phosphate binders.
- Mortality rates remain elevated compared to pre-COVID levels, impacting overall patient volume growth.
- The company faces challenges in achieving its volume growth objectives, with a revised expectation of a year-over-year decline in treatment volume.
Good evening. My name is Michelle, and I will be your conference facilitator today. At this time, I would like to welcome everyone to the DaVita second quarter 2025 earnings call.
(Operator Instructions) Thank you, Mr. Eliason, you may begin your conference.
Thank you, and welcome to our second quarter conference call. We appreciate your continued interest in our company. I'm Nic Eliason, Group Vice President of Investor Relations. And joining me today are Javier Rodriguez, our CEO; and Joel Ackerman, our CFO.
Please note that during this call, we may make forward-looking statements within the meaning of the Federal Securities laws. All of these statements are subject to known and unknown risks and uncertainties that could cause the actual results to differ materially from those described in the forward-looking statements.
For further details concerning these risks and uncertainties, please refer to our second quarter earnings press release and our SEC filings,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
